Correlation Between Inhibikase Therapeutics and Candel Therapeutics
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Candel Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Candel Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and Candel Therapeutics, you can compare the effects of market volatilities on Inhibikase Therapeutics and Candel Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Candel Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Candel Therapeutics.
Diversification Opportunities for Inhibikase Therapeutics and Candel Therapeutics
-0.78 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Inhibikase and Candel is -0.78. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Candel Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Candel Therapeutics and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Candel Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Candel Therapeutics has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Candel Therapeutics go up and down completely randomly.
Pair Corralation between Inhibikase Therapeutics and Candel Therapeutics
Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 1.1 times more return on investment than Candel Therapeutics. However, Inhibikase Therapeutics is 1.1 times more volatile than Candel Therapeutics. It trades about 0.07 of its potential returns per unit of risk. Candel Therapeutics is currently generating about -0.06 per unit of risk. If you would invest 261.00 in Inhibikase Therapeutics on September 4, 2024 and sell it today you would earn a total of 15.00 from holding Inhibikase Therapeutics or generate 5.75% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inhibikase Therapeutics vs. Candel Therapeutics
Performance |
| Timeline |
| Inhibikase Therapeutics |
| Candel Therapeutics |
Inhibikase Therapeutics and Candel Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibikase Therapeutics and Candel Therapeutics
The main advantage of trading using opposite Inhibikase Therapeutics and Candel Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Candel Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Candel Therapeutics will offset losses from the drop in Candel Therapeutics' long position.| Inhibikase Therapeutics vs. Candel Therapeutics | Inhibikase Therapeutics vs. Cingulate Warrants | Inhibikase Therapeutics vs. Unicycive Therapeutics | Inhibikase Therapeutics vs. Cardio Diagnostics Holdings |
| Candel Therapeutics vs. Aerovate Therapeutics | Candel Therapeutics vs. Adagene | Candel Therapeutics vs. Acrivon Therapeutics, Common | Candel Therapeutics vs. Rezolute |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Complementary Tools
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |